Status:

COMPLETED

Platelet PAR-1 Activation in Health and Diabetes

Lead Sponsor:

Vanderbilt University Medical Center

Conditions:

Type 2 Diabetes

Healthy

Eligibility:

All Genders

60+ years

Brief Summary

Platelet activation has been associated with bad events like heart attack and stroke. There are a variety of platelet activators that regulate how active a platelet is. We are interested in Protease-a...

Eligibility Criteria

Inclusion

  • Healthy men and women ≥60 years of age OR
  • Type 2 diabetic men and women ≥60 years of age

Exclusion

  • Active cancer
  • Prior myocardial infarction, prior stroke, diagnosed peripheral artery disease
  • Severe liver (cirrhosis, cancer, or end-stage liver disease), kidney disease (eGFR \<30 cc/min).
  • Pregnancy or lactation
  • Active vasculitis
  • Anticipated lifespan \< 2 years
  • Current use of a DOAC

Key Trial Info

Start Date :

June 1 2018

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

February 2 2021

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT04280549

Start Date

June 1 2018

End Date

February 2 2021

Last Update

March 19 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232